Clinical Trial Update: Evaluation of Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of Bertilimumab in Patients With Active Moderate to Severe Ulcerative Colitis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Bertilimumab for active moderate to severe ulcerative colitis has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Bertilimumab

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe | Phase 2 | Status: TERMINATED | Results posted: 2025-11-25